

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

L-arginine hydrochloride (Brand name: Arginine Injection “AY” 30 g)

January 29, 2025

Therapeutic category

Reagents for various function tests

Non-proprietary name

L-arginine hydrochloride

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

Current	Revision
9. PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACKGROUNDS 9.1 Patients with Complication or History of Diseases, etc. (N/A)	9. PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACKGROUNDS 9.1 Patients with Complication or History of Diseases, etc. <u>Patients with a history of hypersensitivity to any of the ingredients of this drug</u> <u>This drug should not be administered except in cases where such use is considered absolutely necessary for the diagnosis.</u> <u>Anaphylaxis may occur.</u>
11. ADVERSE REACTIONS (N/A)	11. ADVERSE REACTIONS <u>11.1 Clinically Significant Adverse Reactions</u> <u>Anaphylaxis</u>

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.